INFLUENZA VACCINES FOR THE WORLD
19-21 April 2017, CHUV/University of Lausanne, Lausanne, Switzerland

SECOND CIRCULAR AND PROVISIONAL CONFERENCE PROGRAMME FOR IVW 2017

Influenza Vaccines for the World – IVW 2017 is the sixth international conference and exhibition in this important series of influenza vaccine meetings. The IVW conference series focuses on ‘Influenza Vaccination Issues’.

The IVW series is an international forum for world renowned experts in the field of influenza vaccines and related issues (adjuvants/delivery/vaccination strategies) to report on the latest data and trends associated with current and new influenza vaccines/technologies and their availability/delivery/implementation worldwide.

The IVW 2017 Scientific Advisory Panel invites the influenza community worldwide to submit abstracts for consideration for inclusion in the IVW 2017 oral & poster scientific programmes.

SCIENTIFIC ADVISORY PANEL

Othmar Engelhardt (NIBSC/HPA, Potters Bar, UK)
Rosalind Hollingsworth (Sanofi Pasteur, Swiftwater, Pennsylvania, USA)
John Oxford (Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)
Albert Osterhaus (University of Veterinary Medicine Hannover, Hannover, Germany)
Ted Ross (University of Georgia, Athens, Georgia, USA)
Yoshihiro Kawaoka (University of Wisconsin, Madison, Wisconsin, USA)
Helen Bright (MedImmune, Liverpool, UK)
Jonathan Van Tam (University of Nottingham, UK)
Rob Lambkin-Williams (hVIVO Ltd., London, UK)
Dirk Poelaert (GSK Vaccines, Ware, Belgium)
Ronald Kompier (FluConsult, Noordwijk, The Netherlands)
Keiji Fukuda (WHO, Geneva, Switzerland)
Manon Cox (Protein Sciences Corporation, Meriden, Connecticut, USA)
Emanuele Montomoli (VisMederi Srl, Siena, Italy)
Yotam Levin (NanoPass Technologies Ltd, Rehovot, Israel)
Mannoharan Singh (Takeda Vaccines, Morrisville, North Carolina, USA)
Anna-Karin Maltras (Eurocine Vaccines AB, Solna, Sweden)
Edward Remarque (BPRC, Rijswijk, The Netherlands)
Myra Widjojoatmodjo (Janssen Vaccines, Leiden, The Netherlands)
Sean Tucker (VAXART Inc, South San Francisco, California, USA)
Nathalie Charland (Medicago, Quebec, Canada)
Kathy L. Rowlen (InDevR Inc. Boulder, Colorado, USA)

CONFERENCE SCOPE

IVW 2017 will address the following important topics:

- Surveillance Issues / Burden of Disease
- Immunological Issues
- Social / Political / Financial Issues Surrounding Influenza Vaccination
- Novel Developments - Production / Formulation Issues / Manufacturing Issues - Vaccine Usage / Targeting Strategies
- Influenza Vaccines / Adjuvants – Improvement Issues - Pandemic Preparedness Issues / Licensing Issues

The scientific programme will include keynote lectures, contributed papers, workshops, panel discussions, satellite symposia and poster presentations emphasising all aspects of ‘Influenza Vaccines’ and their usage and effectiveness. Potential authors are invited to submit abstracts on any of the above topics for consideration for inclusion within the conference program.

SPECIAL SESSIONS

Universal Influenza Vaccines – Latest Developments
Innate and Acquired Immunity to Plant-Made Influenza VLP Vaccines in Adults & Elderly
IVW 2017 Workshop: Alternative Potency Assay Development for Influenza Vaccines
07.30am
Arrival & Registration & Posters Set-Up

09.30am

SESSION 1: OPENING PLENARY SESSION

Moderator: John Oxford (Queen Mary College, University of London, London, UK)

‘The Global Action Plan (GAP) for influenza vaccines 10 years on’
Erin Sparrow, Martin Friede and Claudia Nannei (WHO, Geneva, Switzerland)

‘Treating the host response to emerging virus diseases: Lessons learned from influenza and ebola, and implications for global health and security’
David Fedson (Independent Consultant, Sergy Haut, France)

‘The challenge of vaccinating healthcare workers against influenza’
Jonathan Van Tam (University of Nottingham, Nottingham, UK)

Coffee Break & Posters Set-Up

SESSION 2: PLENARY II

Moderator: Helen Bright (MedImmune Ltd, Liverpool, Merseyside, UK)

‘Influenza infection in quarantined volunteers for basic studies of a new generation of vaccines and antibody therapies’
John Oxford (Queen Mary College, University of London, London, UK)

‘The past and future of LAIV’
Timo Vesikari (University of Tampere, Tampere, Finland)

‘Beyond hemagglutinin for flu vaccines: A new analytical platform for tracking HA, NA, M1 and NP’
Kathy Rowlen (InDevR Inc., Boulder, Colorado, USA)

Lunch Break & Posters

SESSION 3: INFLUENZA VIRUSES

Moderator: Ted Ross (University of Georgia, Athens, Georgia, USA)

‘Global circulation patterns of seasonal influenza viruses vary with antigenic drift’
Derek Smith (University of Cambridge, Cambridge, UK)

‘Improvement of influenza candidate vaccine viruses’
Othmar G. Engelhardt (NIBSC, South Mimms, Potters Bar, Hertfordshire, UK)

‘Human virus challenge models, from one century to the next: What have we learned?’
Rob Lambkin-Williams (NVIVO Ltd, London, UK)

‘Ferret models to study vaccine strategies against influenza’
Koert Stittelaar1, Leon de Waal1, Geert van Amerongen1, Marie Pohl1, Edwin Veldhuis Kroee2 and Albert Osterhaus1,2,3

(1 Viroclinics Biosciences B.V., Rotterdam, The Netherlands; 2 Artemis One Health, Utrecht, The Netherlands; 3 University of Veterinary Medicine, Hannover, Germany)

‘COBRA HA induced hemagglutination-inhibition antibodies against a panel of H3N2 influenza antigen variants’
Terianne M. Wong1, Anne-Gaelle Bébin-Blackwell1, James D. Allen1, Donald M. Carter1, Timothy Aelftsantis2, Joshua DiNapoli2, Harold Kleanthous1 and Ted M. Ross1

(1 University of Georgia, Athens, Georgia, USA; 2 Sanofi-Pasteur, Inc., Discovery Research, Cambridge, Massachusetts, USA)

‘Emergence and spread of antigenic variants for H3N2 influenza A viruses: Uncertainty and rapidity’
Xiu-Feng Wan, Lei Han, Lei Li and Tong Zhang
(College of Veterinary Medicine, Mississippi State University, Mississippi, USA)

‘A novel amphibian innate immune mediator is virucidal for human influenza viruses’
Joshy Jacob (Emory University, Atlanta, Georgia, USA)

Tea Break & Posters

SESSION 4: INFLUENZA VACCINES

Moderator: Jonathan Van Tam (University of Nottingham, Nottingham, UK)

‘The rationale for quadrivalent influenza vaccines’
Dirk Poelert (GlaxoSmithKline, Ware, Belgium)

‘A role for DNA immunization in preventing influenza infection’
Grant Weaver, Shixia Wang, and Shan Lu (University of Massachusetts Medical School, Worcester, Massachusetts, USA)

‘Broadly protective H5 influenza vaccine: Bettering the standard of care’
Harry Kleanthous1, Timothy Aelftsantis2, Josh Dinapoli2, Stephen Anderson, Thorsten Vogel, Corey J. Crevar1, Donald M. Carter1, Ray Oomen, Mark Parrington1, Nicholas Jackson and Ted M. Ross2

(1 Sanofi-Pasteur, Inc., Research, Cambridge, Massachusetts, USA; 2 University of Athens, Athens, Greece)

‘Pan-influenza A protection from group 1 and 2 viruses provided by X-31 cold-adapted live attenuated influenza vaccine’
Yo Han Jang1, Joo Young Kim2, Young Ho Byun1, Ahyun Son1, Yoon Jae Lee1, Jun Chang3 and Baik Lin Seong3

(1 Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea; 2 Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, South Korea; 3 Vaccine Translational Research Center, Yonsei University, Seoul, South Korea)

‘The effect of age and pre-existing immunity on seroconversion and backboosting in humans vaccinated with FluZone in five consecutive influenza seasons’
Ted M. Ross1, Ivette Nunez1, James D. Allen1, Michael Carlock2, Simon Owino, Simon Delagrave3 and Harold Kleanthous1

(1 University of Georgia, Athens, Georgia, USA; 2 Sanofi-Pasteur, Inc., Discovery Research, Cambridge, Massachusetts, USA)

‘A novel influenza vaccine targeting an epitope of limited variability’
Craig P. Thompson1,2, José Lourenco3, Mathew Edmans4,5, Kreepa Kooßblät1, Duncan Palmer1, George Carrell1, Daniel O’Connor1, Thomas Bowden1, Andrew Pollard4, Nigel J. Temperton5, Teresa Lambe5, Sarah Gilbert5 and Sunetra Gupta6

(1 Department of Zoology, University of Oxford, Oxford, UK; 2 Jenner Institute Laboratories, University of Oxford, UK; 3 Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK; 4 Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, UK; 5 Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK; 6 Division of Structural Biology, University of Oxford, UK)

‘A “magic” sequence to increase immunogenicity of recombinant prokaryotic and eukaryotic antigens’
I. Peube1, S. Margot1, S. Buffin1, H. Boukebza1, A. Pilloud1, C. Pion1, V. Courtois1, L. Potdevin1, S. Commandeur1, V. Marin1, M.C. Bernard1, P. Dinadayala1, D. Poncet1, R. Sodoyer1, J. Haensler1 and I. Legastelois1

(1 Research and Development, Sanofi Pasteur, Marcy L’etoile, France; 2 OTEC, Lyon, France)

IVW 2017 Welcome Drinks Reception & Posters
SESSION 5: SPECIAL SESSION

‘Innate and acquired immunity to plant-made influenza VLP vaccines in adults and elderly’
Moderator: Nathalie Charland (Medicago Inc., Quebec, Canada)

Speakers to be confirmed

Sponsored by MEDICAGO

Coffee Break & Posters

SESSION 6: DELIVERY ROUTES

Moderator: Manmohan Singh
(Takeda Vaccines Inc., Cambridge, Massachusetts, USA)

‘Clinical development of an inactivated nasal influenza vaccine’
Anna-Karin Maltais (Eurocine Vaccines AB, Solna, Sweden)

‘Phase 1 trial of flu vaccination in the skin using a microneedle patch’
Nadine Rouphael (Emory University, Atlanta, Georgia, USA)

‘Jet delivery of DNA: targeting of hemagglutinin to MHC class II molecules protects rhesus macaques against H1N1 influenza’
Petra Mooij1, Gunnveig Grødeland2, Gerrit Koopman1, Daniella Mortier1, Ivonne G. Nieuwenhuis3, Ergin Verschoor1, Willy M. Bogers1,2 and Bjarne Bogen1,2,8

1 Biomedical Primate Research Centre, Rijswijk, The Netherlands; 2 K.G. Jethan Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway; 3 Centre for Immune Regulation (CIR), Institute of Immunology, University of Oslo and Oslo University Hospital, Norway

‘Intranasal immunization with influenza VLPs containing GPI-anchored CCL28 induces strong immune responses conferring heterologous protection’
Baozhong Wang (Georgia State University, Atlanta, Georgia, USA)

‘The cross-protective potential and the protection-relevant immune mechanisms of whole inactivated virus vaccines are determined by adjuvants and route of immunization’
Yoshita Bhide1, Wei Dong1, Inta Gribonika1, Daniëlle Voshart1, Tjarko Meijerhof1, Jacqueline de Vries-Idema1, Dennis Christensen3, Nils Lycke2, Stephen Norley1, Diane Major1, Sarah Skeldon1, Othmar Engelhardt1 and Anke Huckriede1

1 University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; 2 Statens Serum Institut, Copenhagen, Denmark; 3 Gothenburg University, Gothenburg, Sweden; 4 Robert Koch Institute, Berlin, Germany; 5 National Institute for Biological Standards and Control (NIBSC), South Mimms, Potters Bar, Hertfordshire, UK

‘Challenges in influenza virus-like particles production: new analytical tools and downstream process optimization’
S.B. Carvalho1,3, J.M. Freire1, R. Silva1, M.G. Moleirinho1, B. Cunha1,2, A.S. Moreira1, F. Monteiro1,2, D. Gaspar3, M.A.R.B. Castanhão1, G.J.L. Bernardes3,4, D. Wheatley4, J. Welsh1, R. Gantier1, A. Xenopoulos1, P. M. Alves1,2, C. Peixoto1,2 and M.J.T. Carrondo1,2,8

1 ITQB NOVA, Oeiras, Portugal; 2 iBET, Oeiras, Portugal; 3 Instituto de Medicina Molecular, Lisboa, Portugal; 4 University of Cambridge, Cambridge, UK; 5 Pall Life Sciences, UK; 6 Pall Life Sciences, USA; 7 EMD Millipore, USA; 8 FCT/UNL, Capanica, Portugal

Lunch Break & Posters

SESSION 7: UNIVERSAL INFLUENZA VACCINES – I

Moderator: Sean Tucker (VAXART Inc., South San Francisco, California, USA)

‘Improved influenza vaccines: What do we want?’
Justin Ortiz (WHO, Geneva, Switzerland)

‘Progress in clinical development of novel influenza vaccines’
Sarah Gilbert (University of Oxford, Oxford, UK)

‘Potency of H1 mini-HA universal influenza vaccine in the pre-exposed setting’
Harmjan Kuipers and Joan van der Lubbe (Janssen Vaccines and Prevention, Leiden, The Netherlands)

‘Large variation in effects of influenza vaccines pre- and post-2009 influenza H1N1 pandemic among community-dwelling older persons’
E. Hak (University Groningen, Groningen, The Netherlands)

Tea Break & Posters

SESSION 8: IVW 2017 WORKSHOP

‘Alternative potency assay development for influenza vaccines’
Moderators: Jon C. Bundy1, Carrie L. Pierce2 and Othmar G. Engelhardt2
1 National Center for Environmental Health, Centers for Disease Control and Prevention (NCEH/CDC), Atlanta, GA USA; 2 National Institute for Biological Standards and Control (NIBSC), South Mimms, Potters Bar, Hertfordshire, UK

‘Opening Remarks’
Othmar Engelhardt (National Institute for Biological Standards and Control (NIBSC), South Mimms, Potters Bar, Hertfordshire, UK)

‘Historical and current background on potency assays for vaccines’
Jerry Weir (Center for Biologics Evaluation and Research, Food and Drug Administration (CFBA/FAA) Baltimore, Maryland, USA)

‘Basis for measurement in novel influenza potency assays’
Ethan September (Sequiris, Cambridge, Massachusetts, USA)

‘Analytical challenges for developing alternative potency assays’
Terry Cyr (Health Canada, Ottawa, Ontario Canada)

‘Use of mass spectrometry based standards for improving the influenza vaccine development pipeline’
Carrie Pierce (National Center for Environmental Health, Centers for Disease Control and Prevention (NCEH/CDC), Atlanta, Georgia, USA)

‘IFPMA/BARDA support in development of alternative potency assays’
To Be Confirmed

‘Status of current approaches for novel alternative potency assays’
Jon Bundy (National Center for Environmental Health, Centers for Disease Control and Prevention (NCEH/CDC), Atlanta, Georgia, USA)

‘Progress of IFPMA/BARDA phase II potency assay comparison study’
To Be Confirmed – NIBSC Speaker

General Discussion
Closing Remarks

SECURE ON-LINE REGISTRATION IS NOW OPEN AT: www.meetingsmanagement.com/ivw_2017
SESSION 9: UNIVERSAL INFLUENZA VACCINES – II
Moderator: Sarah Gilbert (University of Oxford, Oxford, UK)

‘What is needed for the ultimate influenza vaccine?’
Rob Lambkin-Williams (hVIVO Ltd, London, UK)

‘Universal influenza vaccine based on conserved antigen: Proof of concept studies’
Ze Chen (Shanghai Institute of Biological Products Co., Ltd., Shanghai, China)

‘Recombinant adenosine expressing influenza HA can effectively prime for heterologous neutralizing antibody responses’
Sean Tucker (VAXART Inc., South San Francisco, California, USA)

‘Results of a Phase 1a study of M2SR influenza vaccine in healthy adults’
Pamuk Bilisel (FluGen Inc., Madison, Wisconsin, USA)

‘Human quarantine experiments contribute to the science of universal influenza vaccines’
John Oxford (Queen Mary College, University of London, London, UK)

‘Safety and immunogenicity of a BiondVax-developed universal influenza vaccine (Multimeric-001) followed by an administration of a H5N1 influenza vaccine’
Tamar Ben-Yedidia, Eva van Doorn, Attila Islam, Shimon Hassin, Ilidio Visontai, Stephan Noriery, Arne Hukecied, Hendrik W. Frijlink and Eelko Hak

‘Recombinant influenza vaccines are matched and have an efficacy of 50-70%, do you show a benefit’
Ab Osterhaus (University of Veterinary Medicine Hannover, Hannover, Germany)

‘Influenza prevention: Vaccination uptake stagnation – a global public health failure?’
Bram Palache (Independent Consultant, IFPMA, International Federation of Pharmaceutical Manufacturers & Associations, Geneva, Switzerland)

‘Public Health issues around switching from seasonal to pandemic vaccine production’
Gary Grohmann (University of Veterinary Medicine Hannover, Hannover, Germany)

‘How do we evaluate novel vaccines with unknown correlates of protection. What do we mean by vaccine efficacy. How, when most years seasonal vaccines are matched and have an efficacy of 50-70%, do you show a benefit for a mismatched strain. What is the role of ex-vivo models?’
Conference Close & Departure

* This provisional programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.

SESSION 10: FORMULATION, VACCINATION & REACTOGENICITY
Moderator: Rob Lambkin-Williams (hVIVO Ltd, London, UK)

‘Rational vaccine formulation development using QbD Principles’
Mannohann Singh (Takeda Vaccines, Inc., Cambridge, Massachusetts, USA)

‘Vaccinating in the presence of pre-existing immune responses’
Donald M. Carter, Christopher A. Darby, Timothy Alefantisi, Joshua DiNapoli, Harold Kleanthous and Ted M. Ross

‘Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge’
Christopher Karch, Jianping Li, Caroline Kulaangara, Sara M. Paulillo, Senthil K. Ramani, Sharareh Emadi, Armin Tar, Zeinab H. Helali, Qing Fan, Mazhar I. Khan and Peter Burkhard

‘Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: Results from a feasibility study’
Anke L. Susman, Thomas Verstraeten and Antoon De Schryver

‘Infection-permissive immunity against influenza virus provided by vaccination prevents loss of alveolar macrophages and modulates virus-induced cross-reactive cellular immune responses during subsequent influenza infections’
Angela Choi, Joeselin Andrea Morales Mina, Jan Spitaels, Adolfo Garcia-Sastre and Michael Scholsart

‘Impact of prior influenza exposures on H3N2 cross-reactivity of human post-vaccination sera’
Hang Xie, Lei Li, Zhiping Ye, Xing Li, Ewan P. Plant, Olga Zoueva, Yangqing Zhaor, Xianghong Jing, Zhengshi Lin, Toshiaki Kawano, Meng-Jung Chiang, Courtney Finch, Martina Kosikova, Anding Zhang, Yanhong Zhu and Xu-Feng Wani

(1) Center for Biologics Evaluation and Research, United States Food and Drug Administration (CBER/FDA), Silver Spring, Maryland, USA; (2) Mississippi State University, Sissippi, USA)

Lunch Break & Posters
REGISTRATION

Delegates should register for IVW 2017 by completing the form provided on the back page of this brochure. The completed Conference Registration Form plus payment (in £ Pounds Sterling) should be sent to the IVW 2017 Conference Manager – Caroline Sumner at Meetings Management. The IVW 2017 Conference Registration Desk will be open from 8.00am on Wednesday 19th April 2017.

Delegates can also register securely on-line at:
www.meetingsmanagement.com/ivw_2017

VENUE & ACCOMMODATION

IVW 2017 will be held at:
CHUV, Lausanne, Switzerland

Accommodation: there are numerous hotels in Lausanne to suit most budgets. For information details on accommodation in Lausanne and other useful information, please visit:
http://www.lausanne-tourisme.ch/en/

Please note that the IVW 2017 conference organizers will not be recommending any specific hotels in Lausanne.

April is a busy time in Lausanne and it is recommended that IVW 2017 delegates book their accommodation without delay.

PUBLICATION

A USB storage device containing the final programme and abstracts of all presentations, oral and poster, will be distributed to delegates when they register at the conference.

TABLE TOP EXHIBITION

Table Top Exhibition space is available at the meeting. Exhibitors can showcase their products or services by reserving a table top exhibit. The exhibit area will be located where all refreshments breaks will be taken to ensure maximum traffic of conference delegates. If you are registering for the conference, you can reserve a table for £4995. If you do not wish to attend the conference sessions, you can reserve a table for £5995 (includes admission to all meals/receptions by one company representative).

PLEASE NOTE: If you wish to have additional representatives on your table top exhibit there will be an additional charge for catering levied per head. Please contact the Conference Manager for this additional price.

Please make your bookings and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Delegate Pack Insertion facilities at IVW 2017 should be directed to John Herriot at Meetings Management (E-mail: jherriot@meetingsmgmt.u-net.com).

PLEASE NOTE: Literature for distribution to IVW 2017 delegates is subject to approval by the conference organizers.

INSURANCE & CANCELLATION

The organizers cannot be held responsible for any personal accident or damage to their private property of participants at IVW 2017. The organizers strongly urge participants to ensure they have adequate travel and personal insurance cover before they depart for the conference. The organizers cannot be held liable for any costs incurred should the conference be cancelled for any reason. Maximum notice of cancellation will be given by the organizers to all pre-registered delegates.

PROGRAMME

The IVW 2017 Scientific Advisory Panel and the IVW 2017 Conference Organizers reserve the right to alter any part of the published provisional conference programme if this is necessitated by any circumstances outside their control. All efforts will be made to keep any such changes to a minimum. The provisional programme published in the brochure was correct at the time of going to press.

CANNOT ATTEND?

If you and your colleagues are unable to attend the conference, the conference materials (abstract booklet, speaker handouts, late abstracts, attendee list, pack materials and literature) are available for purchase. While not intended as a substitute for actual attendance, these materials would at least provide a documentary record of the event and allow you to keep you or your organization’s library up to date. The cost of providing this non-attendee package is £595 (including postage and packing). To order this package from Meetings Management please use the relevant section in the Delegates Registration Form on the back page of this brochure.

ANY QUESTIONS?

For further information and assistance, please contact: Caroline Sumner, IVW 2017 Conference Manager:
IVW 2017 Conference Secretariat, Meetings Management
The Old Dairy Tower, Peper Harow Park, Godalming
Surrey, GU8 6BD, United Kingdom.
Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
E-mail: csumner@meetingsmgmt.u-net.com

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 31st March 2017. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 31st March 2017.
Please tick appropriate boxes and write clearly in BLOCK CAPITALS or type.

Surname .................................................................................................................. First Name ........................................................................................................ Title ..................................................................................................................
Organization ........................................................................................................... Address ................................................................................................................
........................................................................................................................................
Country ............................................................................................................... Telephone ......................................................................................................... Fax ......................................................................................................................
E-mail (plain type or print): ..................................................................................
If you are an EC business please state your VAT registration number: ..............

Disabled (please state any special needs): ............................................................ Special diet (please state requirements): ............................................................

REGISTRATION FEES

<table>
<thead>
<tr>
<th>Speaker/Delegate Registration Fees: (Please tick appropriate section)</th>
<th>(NOTE THAT FEES ARE IN UK £ STERLING)</th>
<th>DELEGATE REGISTRATION FORMS NOT DULY &amp; FULLY COMPLETED WILL NOT BE VALID</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ Speaker Registration (submitted oral/poster papers) ( בהקטנה לטלק)</td>
<td>£795.00</td>
<td>Amount Due (£ Sterling)</td>
</tr>
<tr>
<td>(Payment must be received before Friday 27th January 2017)</td>
<td>£</td>
<td></td>
</tr>
<tr>
<td>□ Reduced Early Bird Registration (ammers צללח מאט)</td>
<td>£995.00</td>
<td>£</td>
</tr>
<tr>
<td>(Payment must be received before Friday 27th January 2017)</td>
<td>£</td>
<td></td>
</tr>
<tr>
<td>□ Full Registration (Kate הדרים מלאים)</td>
<td>£1195.00</td>
<td>£</td>
</tr>
<tr>
<td>(Payment received after Friday 27th January 2017)</td>
<td>£</td>
<td></td>
</tr>
<tr>
<td>□ Student Registration (K工業 סטודנטים)</td>
<td>Price on application</td>
<td>£</td>
</tr>
</tbody>
</table>

Table Top Exhibits/Delegate Pack Inserts

| □ Table Top Exhibit (I am registered to attend) (For those使える is) | £4995.00 | £ |
| (Payment must be received before Friday 27th January 2017) | £ | | |
| □ Table Top Exhibit (I am NOT registered to attend) (For those שלא are) | £5995.00 | £ |
| (Payment must be received before Friday 27th January 2017) | £ | | |
| □ Delegate Pack Insert (For those使える is) | £745.00 | £ |
| (Payment must be received before Friday 27th January 2017) | £ | | |

For those Unable to Attend

| □ Set(s) of IVW 2017 materials (For those нельзя is) | @ £595.00 (per set) | £ |
| (Payment must be received before Friday 27th January 2017) | £ | | |

Total Amount Payable

£

Registration fees include admission to all conference sessions, morning and afternoon refreshments and lunches on the 19th, 20th and 21st April 2017.

PAYMENT

□ I enclose a cheque for £.......................... made payable to Meetings Management. (Delegates registering from outside the UK must ensure that cheques are drawn on a London Bank. Please quote IVW 2017 on the reverse of the cheque.)

□ I have made a payment by bank transfer (quoting IVW 2017 on the transfer documentation) to Barclays Bank, Barclays Business Centre, Guildford Branch, PO Box 33, Guildford, Surrey GU1 3AN, UK:

UK Pounds Sterling Account: Meetings Management 0040614335, IBAN GB02BARC20353540614335 SWIFT/TIC BARCB22
US Dollar Account: Meetings Management 53209211, IBAN GB77BARC20353553209211 SWIFT/TIC BARCB22

Euro Account: Meetings Management 59179600, IBAN GB91BARC20353559179600 SWIFT/TIC BARCB22

All transfer charges must be paid by the sender. Delegates paying by this method are requested to send the Conference Manager a copy of the bank transfer. Payments made by bank transfer must have £15.00 added to the total. PLEASE NOTE THAT IT WILL NOT BE POSSIBLE TO PAY REGISTRATION FEES BY BANK TRANSFER AFTER FRIDAY 24TH FEBRUARY 2017. LATE PAYMENT AFTER FRIDAY 24TH FEBRUARY 2017 MUST BE MADE BY CREDIT CARD (VISA/MASTERCARD/AMEX).

□ I would like to pay £.......................... by credit card (VISA/MasterCard/AMEX only accepted).

Card no. ................................................................. 3 Digit Security Code (AMEX: 4 Digits) ................................................................. Expiry Date .................................................. Registered Card Address ..................................

Please remember that any remittance sent but not received by the time of the conference must be paid again at the Registration desk: we will refund you after the conference. Cancellations received before Friday 24th February 2017 will be refunded in full less an administrative charge of £225 per person. Refunds will not be possible if a cancellation is received after Friday 24th February 2017. Substitutions can be made at any time prior to the conference. Please inform the Conference Manager of any changes. We strongly advise that delegates purchase travel insurance to cover any unforeseen circumstances and protect against loss of hotel deposits and registration fees.

VAT No. 591 617618

Signature .................................................................................................................. Date ..........................................................................................................

PLEASE RETURN THIS FORM TO:

IVW 2017 CONFERENCE SECRETARIAT, MEETINGS MANAGEMENT
The Old Dairy Tower, Peper Harow Park, Godalming, Surrey GU8 6BD, United Kingdom
Conference Manager: Caroline Sunner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516 E-mail: csumner@meetingsmgmt.u-net.com

SECURE ON-LINE REGISTRATION IS NOW OPEN AT: www.meetingsmanagement.com/ivw_2017